SCHEMBL26617837

SCHEMBL26617837

O=C(O)c1cc2cc(F)ccc2nc1N1CCCC(F)(F)CC1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 15/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAOB P27338 2/20 0.38
▸ JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26617697 0.91 SCN10A (0.40) SCN10AALDH1A1MAOBJAK2
SCHEMBL30681918 0.88 FABP3 (0.44) SCN10AMAOB
SCHEMBL26617770 0.88 FABP3 (0.44) SCN10AMAOB
SCHEMBL26617864 0.87 SCN10A (0.44) SCN10A
SCHEMBL26617935 0.86 SCN10A (0.39) SCN10A
SCHEMBL26617769 0.86 ALDH1A1 (0.46) SCN10AALDH1A1MAOB
SCHEMBL26618013 0.86 SCN10A (0.44) SCN10A
SCHEMBL26617826 0.85 MEN1 (0.48) SCN10AALDH1A1MAOB
SCHEMBL31345642 0.83 SCN10A (0.42) SCN10A
SCHEMBL26617474 0.83 SCN10A (0.42) SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 — — CN disclosed
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 — — EP disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
Send feedback